Publications Non-Small Cell Lung Cancer

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu MD, Thomas Brodowicz MD, Prof Christoph Zielinski MD, Joo Hang Kim MD, Prof Maciej Krzakowski MD, Eckart Laack MD, Prof Yi-Long Wu MD, Isabel Bover MD, Stephen Begbie MD, Valentina Tzekova MD, Branka Cucevic MD, Jose Rodrigues Pereira MD, Sung Hyun Yang MD, Jayaprakash Madhavan MD, Katherine P Sugarman MD, Patrick Peterson PhD, William J John MD, Kurt Krejcy MD, Dr Chandra P Belani MD.

    Lancet 2009; 374; Issue 9699, Pages 1432-1440, 24 October 2009

  • Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study.

    T. Ciuleanu, T. Brodowicz, CP. Belani, JH Kim. M. Krzakowski, E. Laack, YL. Wu, P. Peterson, S. Adachi, C. Zielinski

    J. Clin. Oncol (supplement to 26) 2008: # 8011

  • Tolerability of pemetrexed versus placebo as a maintenance therapy in advanced non-Small Cell Lung Cancer: Evidence from a large randomized study.

    C. Zielinski, S. Yang, A. Santoro, R. Ramlau, A. Liepa, P. Peterson, T. Brodowicz, J. Madhavan, F. Franke, B. Cucevic

    J. Clin. Oncol (supplement to 26) 2008: # 8060

  • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

    Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T, Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C, Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European Cooperative Oncology Group CECOG.

    Lung Cancer. 2006 May; 52(2): 155-63. Epub 2006 Mar 29.

  • Gemcitabine and Cisplatin (GC) +/- Subsequent Maintenance Therapy with Single-Agent Gemcitabine in Advanced Non-small Cell Lung Cancer (NSCLC): Preliminary Results of a Randomized Trial of the Central European Cooperative Oncology Group (CECOG).

    M. Krzakowski, M. Wenczl, T. Brodowicz, V. Tzekova, R. Ramlau, N. Ghilezan, B. Cucevic, E. Ulsperger, C. Zielinski, M. Zwitter.

    Proc. Am. Soc. Clin. Oncol. 2004

  • Delay in time to worsening of symptoms of advanced non-small cell lung cancer patients using gemcitabine maintenance therapy.

    P. Peterson, M. Zwitter, M. Krzakowski, M. Wenczl, V. Tzekova, R. Ramlau, T. Ciuleanu, A. Liepa, C. Zielinski, T. Brodowicz

    Supplement to Journal of Clin. Oncol. 2006, 24, 399s, abstract 7140

  • Consensus on Medical Treatment of Non-Small-Cell Lung Cancer

    Central European Cooperative Oncology Group(CECOG); Advisory Committee on Collaboration with Industry in Medical Education of the European School of Oncology (ESO); Vienna Medical Association.

    Lung Cancer. 2002 Dec; 38 Suppl 3:S3-7

  • Consensus on Medical Treatment of Non-Small-Cell Lung Cancer – Update 2004

    Lung Cancer (2005) 50, 129-137

  • Third CECOG Consensus on the Systemic Treatment of Non-Small-Cell Lung Cancer.

    Brodowicz T, Ciuleanu T, Crawford J, Filipits M, Fischer JR, Georgoulias V, Gridelli C, Hirsch FR, Jassem J, Kosmidis P, Krzakowski M, Manegold C, Pujol JL, Stahel R, Thatcher N, Vansteenkiste J, Minichsdorfer C, Zöchbauer-Müller S, Pirker R, Zielinski CC; for the Central European Cooperative Oncology Group (CECOG).

    Ann Oncol. 2011 Sep 22 (Epub ahead of print)

For publications of the results of the Consensus Conferenences
see Consensus Statements »